Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

Topline results were announced from a phase 3 trial evaluating solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime sleepiness (EDS).

Compared with placebo, pitolisant 20 and 40 mg had a greater treatment response for residual excessive daytime sleepiness ... and an Epworth Sleepiness Scale (ESS) score of 14.9, 14.2, and 14.0 ...

If you have a long-term sleep disorder that causes excessive daytime sleepiness (EDS), you may need to take medicines to manage your symptoms. The different medicines available for these ...

Carosella, MD Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive ... placebo (19%; n = 11 vs. 10%; n = 6). The study noted that reported adverse events ...

Alkermes plc (Nasdaq: ALKS) today announced the initiation of Vibrance-3, a phase 2 clinical study evaluating the safety and efficacy of ALKS 2680 compared to placebo in adults with idiopathic ...

with and without severe excessive daytime sleepiness (EDS). In the overall patient population, the study did not demonstrate a statistically significant change on the Montgomery-Åsberg Depression ...

Investigating Sunosi as a treatment for MDD patients with and without excessive daytime sleepiness (EDS), a phase 3, proof-of-concept study did not meet its primary endpoint, Axsome said Tuesday.

Women with increasing 24-hour sleepiness ... in greater daytime sleep needs. Inflammation and vascular risk may [also] be contributing factors. Disrupted sleep patterns and excessive sleep are ...